Journal
CANCER LETTERS
Volume 293, Issue 2, Pages 144-157Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2010.01.015
Keywords
MYCN; Microarrays; Neuroblastoma; Target genes
Categories
Funding
- Cancer Research, UK
- Department of Health Clinician Scientist Award
- National Health and Medical Research Council of Australia
- Cancer Institute New South Wales
- Cure for Life Foundation
- Cancer Council New South Wales
Ask authors/readers for more resources
The MYCN oncogene encodes a transcription factor which is amplified in up to 40% of high risk neuroblastomas. MYCN amplification is a well-established poor prognostic marker in neuroblastoma, however the role of MYCN expression and the mechanisms by which it acts to promote an aggressive phenotype remain largely unknown. This review discusses the current evidence identifying the direct and indirect downstream transcriptional targets of MYCN from recent studies, with particular reference to how MYCN affects the cell cycle, DNA damage response, differentiation and apoptosis in neuroblastoma. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available